Vitravene™—Another Piece in the Mosaic
1998; Mary Ann Liebert, Inc.; Volume: 8; Issue: 4 Linguagem: Inglês
10.1089/oli.1.1998.8.vii
ISSN2168-6599
Autores Tópico(s)CRISPR and Genetic Engineering
ResumoAntisense and Nucleic Acid Drug DevelopmentVol. 8, No. 4 Vitravene™—Another Piece in the MosaicSTANLEY T. CROOKESTANLEY T. CROOKESearch for more papers by this authorPublished Online:30 Jan 2009https://doi.org/10.1089/oli.1.1998.8.viiAboutSectionsPDF/EPUB Permissions & CitationsPermissionsDownload CitationsTrack CitationsAdd to favorites Back To Publication ShareShare onFacebookTwitterLinked InRedditEmail "Vitravene™—Another Piece in the Mosaic." , 8(4), pp. vii–viiiFiguresReferencesRelatedDetailsCited byPost-transcriptional gene silencing by nucleic acid gapmers: a promising therapeutic modality for cancerEpigenomics, Vol. 15, No. 2Antisense RNA Therapeutics: A Brief Overview1 January 2022BIOANALYSIS AND BIOTRANSFORMATION OF OLIGONUCLEOTIDE THERAPEUTICS BY LIQUID CHROMATOGRAPHY‐MASS SPECTROMETRY26 June 2020 | Mass Spectrometry Reviews, Vol. 40, No. 4Inhibition of RNA-binding proteins with small molecules15 July 2020 | Nature Reviews Chemistry, Vol. 4, No. 9Trojan Microparticles Potential for Ophthalmic Drug DeliveryCurrent Medicinal Chemistry, Vol. 27, No. 4PEGylation of therapeutic oligonucletides: From linear to highly branched PEG architectures6 July 2018 | Nano Research, Vol. 11, No. 10Oligonucleotide therapeutics in neurodegenerative diseases1 June 2018 | RNA Biology, Vol. 12Chromatographic approaches for the characterization and quality control of therapeutic oligonucleotide impurities4 October 2017 | Biomedical Chromatography, Vol. 32, No. 1Phytoconstituents—Active and Inert Constituents, Metabolic Pathways, Chemistry and Application of Phytoconstituents, Primary Metabolic Products, and Bioactive Compounds of Primary Metabolic Origin24 June 2018Review on investigations of antisense oligonucleotides with the use of mass spectrometryTalanta, Vol. 176Delivery System Targeting Hemagglutinin of Influenza Virus A to Facilitate Antisense-Based Anti-H1N1 Therapy7 July 2017 | Bioconjugate Chemistry, Vol. 28, No. 7Synthetic nanocarriers for the delivery of polynucleotides to the eyeEuropean Journal of Pharmaceutical Sciences, Vol. 103Liquid chromatographic separation of oligonucleotidesInhibition of clinical pathogenic herpes simplex virus 1 strains with enzymatically created siRNA pools30 May 2016 | Journal of Medical Virology, Vol. 88, No. 12Delivery of Genes and Oligonucleotides25 March 2016Gene Suppression with Chitosan NanoparticlessiRNA Versus miRNA as Therapeutics for Gene SilencingMolecular Therapy - Nucleic Acids, Vol. 4Intravitreal Injection of Splice-switching Oligonucleotides to Manipulate Splicing in Retinal CellsMolecular Therapy - Nucleic Acids, Vol. 4A mildly inducible and selective cross-link methodology for RNA duplexes1 January 2014 | Org. Biomol. Chem., Vol. 12, No. 6Small RNA- and DNA-based gene therapy for the treatment of liver cirrhosis, where we are?World Journal of Gastroenterology, Vol. 20, No. 40Nano-encapsulation of Oligonucleotides for Therapeutic Use13 September 2013Structural modification of siRNA for efficient gene silencingBiotechnology Advances, Vol. 31, No. 5Identification of a T7 RNA polymerase variant that permits the enzymatic synthesis of fully 2′-O-methyl-modified RNAJournal of Biotechnology, Vol. 167, No. 3Complex between Human RNase HI and the phosphonate-DNA/RNA duplex: Molecular dynamics studyJournal of Molecular Graphics and Modelling, Vol. 44Non-viral gene delivery strategies for gene therapy: a “ménage à trois” among nucleic acids, materials, and the biological environment24 February 2013 | Journal of Nanoparticle Research, Vol. 15, No. 3Nano and microtechnologies for ophthalmic administration, an overviewJournal of Drug Delivery Science and Technology, Vol. 23, No. 2Biochemistry of Nucleic Acids Functionalized with Sulfur, Selenium, and Tellurium: Roles of the Single-Atom Substitution5 December 2013RNA Interference Pathways and Therapeutic Exploitation14 September 2012A One-Step Solid Phase Extraction Method for Bioanalysis of a Phosphorothioate Oligonucleotide and Its 3′ n-1 Metabolite from Rat Plasma by uHPLC–MS/MS28 July 2012 | The AAPS Journal, Vol. 14, No. 4Clinical Expert Panel on Monitoring Potential Lung Toxicity of Inhaled Oligonucleotides: Consensus Points and Recommendations Eric W. Alton, Homer A. Boushey, Holger Garn, Francis H. Green, Michael Hodges, Richard J. Martin, Robert D. Murdoch, Harald Renz, Stephen B. Shrewsbury, Rosanne Seguin, Graham Johnson, Joel D. Parry, Jeff Tepper, Paolo Renzi, Joy Cavagnaro, and Nicolay Ferrari22 August 2012 | Nucleic Acid Therapeutics, Vol. 22, No. 4Gene therapy in neurology: review of ongoing clinical trialsClinical Investigation, Vol. 2, No. 6Absence of Unspecific Innate Immune Cell Activation by GATA-3-Specific DNAzymes Tanja Dicke, Isabella Pali-Schöll, Andreas Kaufmann, Stefan Bauer, Harald Renz, and Holger Garn5 April 2012 | Nucleic Acid Therapeutics, Vol. 22, No. 2Determination of therapeutic oligonucleotides using capillary gel electrophoresis6 September 2011 | Biomedical Chromatography, Vol. 26, No. 4Chromatographic methods for the determination of therapeutic oligonucleotidesJournal of Chromatography B, Vol. 883-884RNA therapeutics: beyond RNA interference and antisense oligonucleotides20 January 2012 | Nature Reviews Drug Discovery, Vol. 11, No. 2Nucleic Acids as Therapeutics21 May 2012Oligonucleotide Conjugates: Rationale, Synthesis, and Applications21 May 2012Antisense Technology: From Unique Laboratory Tool to Novel Anticancer Treatments21 May 2012Pathogenic exon-trapping by SVA retrotransposon and rescue in Fukuyama muscular dystrophy5 October 2011 | Nature, Vol. 478, No. 7367Structures and Functions of Nucleic Acids Modified With S, Se, and Te and Complexed with Small Molecules25 July 2011In vitro and in vivo characterisation of a novel c-FLIP-targeted antisense phosphorothioate oligonucleotide4 August 2010 | Apoptosis, Vol. 15, No. 12Brain Tumor Therapy with Antisense Oligonucleotides30 July 2009Selective Photo-Cross-Linking of 2′- O -Psoralen-Conjugated Oligonucleotide with Rnas Having Point Mutations4 April 2007 | Nucleosides, Nucleotides and Nucleic Acids, Vol. 26, No. 3Antisense-based cancer therapeutics: are we there yet?24 April 2006 | Expert Opinion on Emerging Drugs, Vol. 11, No. 2ANTISENSE STRATEGIES FOR THE DEVELOPMENT OF NOVEL CANCER THERAPEUTICSThe Future of Antisense Oligonucleotides in the Treatment of Respiratory DiseasesBioDrugs, Vol. 20, No. 1Phosphate Mimic of Nucleotides, Conformational Influences on the Ribofuranose ConformationsHETEROCYCLES, Vol. 67, No. 2Synthesis of oligodeoxyribonucleotides containing hydroxymethylphosphonate bonds in the phosphoramidite method and their hybridization propertiesTetrahedron Letters, Vol. 46, No. 51DNA-based therapeutics and DNA delivery systems: A comprehensive reviewThe AAPS Journal, Vol. 7, No. 1Cell-Specific Targeting of Lipid-Based Carriers for ODN and DNA9 December 2008 | Journal of Liposome Research, Vol. 15, No. 1-2Desulfurization of aromatic polysulfides with triphenylphosphineJournal of Sulfur Chemistry, Vol. 25, No. 2-3Radiosensitization by Antisense Anti-MDM2 Mixed-Backbone Oligonucleotide in in Vitro and in Vivo Human Cancer Models20 February 2004 | Clinical Cancer Research, Vol. 10, No. 4Antisense therapeutics: from theory to clinical practicePharmacology & Therapeutics, Vol. 99, No. 1Repair of a Splicing Defect in Erythroid Cells from Patients with β-Thalassemia/HbE DisorderMolecular Therapy, Vol. 6, No. 6Tumor-targeting, Systemically Delivered Antisense HER-2 Chemosensitizes Human Breast Cancer Xenografts Irrespective of HER-2 Levels1 August 2002 | Molecular Medicine, Vol. 8, No. 8Fully solvated molecular dynamics simulations of duplexes formed by modified oligonucleotides with xylo/phosphodiesteric and xylo/phosphonate internucleoside linkages and their natural counterpartComputer Physics Communications, Vol. 147, No. 1-2Downregulation of human polo-like kinase activity by antisense oligonucleotides induces growth inhibition in cancer cells7 May 2002 | Oncogene, Vol. 21, No. 20In Vivo Pro-Apoptotic and Antitumor Efficacy of a c-Raf Antisense Phosphorothioate Oligonucleotide: Relationship to Tumor Size Quek Choon Lau, Tatjana V. Achenbach, Oliver Borchers, Rolf Müller, and Emily P. Slater8 July 2004 | Antisense and Nucleic Acid Drug Development, Vol. 12, No. 1Nuclear antisense effects of neutral, anionic and cationic oligonucleotide analogs1 October 2001 | Nucleic Acids Research, Vol. 29, No. 19Photo-Cross-Linked Oligonucleotide Duplex as a Decoy-DNA for Inhibition of Restriction Endonuclease ActivityBioorganic Chemistry, Vol. 29, No. 4Antisense oligonucleotides in cutaneous therapyPharmacology & Therapeutics, Vol. 90, No. 1Tailor-made core-shell nanospheres for antisense oligonucleotide delivery: IV.Adsorption/release behaviourJournal of Biomaterials Science, Polymer Edition, Vol. 12, No. 12Antisense Inhibition of IGF Receptor Expression in HaCaT Keratinocytes: A Model for Antisense Strategies in Keratinocytes P.J. WHITE, R.D. FOGARTY, G.A. WERTHER, and C.J. WRAIGHT30 January 2009 | Antisense and Nucleic Acid Drug Development, Vol. 10, No. 3Potent and nontoxic antisense oligonucleotides containing locked nucleic acids9 May 2000 | Proceedings of the National Academy of Sciences, Vol. 97, No. 10Antisense therapeutics: is it as simple as complementary base recognition?Molecular Medicine Today, Vol. 6, No. 2Antitumor activity and pharmacokinetics of a mixed-backbone antisense oligonucleotide targeted to the RIα subunit of protein kinase A after oral administration23 November 1999 | Proceedings of the National Academy of Sciences, Vol. 96, No. 24Detection of Proteins Binding to Short RNA.DNA Hybrids or Short Antisense Oligonucleotides in Xenopus laevis Oocytes and Human Macrophage Cell Extracts by Photoaffinity Radiolabeling FRÉDÉRIC REVERS, MURIEL CARIO, TUONG LUAN CAO, and CHRISTIAN CAZENAVE30 January 2009 | Antisense and Nucleic Acid Drug Development, Vol. 9, No. 4Nucleic Acid BiotechnologyAnnual Review of Biomedical Engineering, Vol. 1, No. 1Antisense Oligonucleotides with Different BackbonesJournal of Biological Chemistry, Vol. 274, No. 31Phosphorothioate oligodeoxyribonucleotides inhibit ribonuclease L thereby disabling a mechanism of interferon actionBioorganic & Medicinal Chemistry Letters, Vol. 9, No. 6Understanding the Translation Regulatory Mechanisms to Improve the Efficiency and the Specificity of Protein Production by the Cell FactoryAntisense approaches in drug discovery and developmentAntisense TechnologyCombination of Gene Therapy with Radiation Volume 8Issue 4Aug 1998 To cite this article:STANLEY T. CROOKE.Vitravene™—Another Piece in the Mosaic.Antisense and Nucleic Acid Drug Development.Aug 1998.vii-viii.http://doi.org/10.1089/oli.1.1998.8.viiPublished in Volume: 8 Issue 4: January 30, 2009PDF download
Referência(s)